CAS 38609-97-1|2-(9-Oxoacridin-10(9H)-yl)acetic acid
| Common Name | 2-(9-Oxoacridin-10(9H)-yl)acetic acid | ||
|---|---|---|---|
| CAS Number | 38609-97-1 | Molecular Weight | 253.253 |
| Density | 1.4±0.1 g/cm3 | Boiling Point | 486.6±34.0 °C at 760 mmHg |
| Molecular Formula | C15H11NO3 | Melting Point | -289ºC (dec.) |
| MSDS | ChineseUSA | Flash Point | 248.1±25.7 °C |
| Symbol | GHS07 | Signal Word | Warning |
Names
| Name | 9-Oxo-10(9H)-acridineacetic acid |
|---|---|
| Synonym | More Synonyms |
2-(9-Oxoacridin-10(9H)-yl)acetic acid BiologicalActivity
| Description | Cridanimod is a small-molecule immunomodulator and interferon inducer[1]. Cridanimod is a potent progesterone receptor (PR) activator mediated through induction of IFNα and IFNβ expression[2]. |
|---|---|
| Related Catalog | Signaling Pathways >>Others >>Progesterone ReceptorSignaling Pathways >>Immunology/Inflammation >>IFNARResearch Areas >>Inflammation/Immunology |
| Target | PR, IFNα, IFNβ[1] |
| In Vivo | Cridanimod (IM; 1-6 mg; twice a week) has a significantly longer survival time. Cridanimod significant increases in IFNα and -β in cridanimod-treated mice in a dose-dependent manner[1]. Animal Model: Athymic mice with hec50co cells[1] Dosage: 1, 3, 6 mg Administration: IM; twice a week Result: Had a significantly longer survival time. |
| References | [1]. Xenetic Biosciences Announces FDA Acceptance of Investigational New Drug Application to Initiate Phase 2 Clinical Trial of Virexxa® in Endometrial Cancer. AUGUST 19, 2016 [2]. Matthew J. Carlson, et al. Cridanimod and progestin therapy in hormone-resistant endometrial cancer. Journal of Clinical Oncology, January 30, 2017. |
Chemical & Physical Properties
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 486.6±34.0 °C at 760 mmHg |
| Melting Point | -289ºC (dec.) |
| Molecular Formula | C15H11NO3 |
| Molecular Weight | 253.253 |
| Flash Point | 248.1±25.7 °C |
| Exact Mass | 253.073898 |
| PSA | 59.30000 |
| LogP | 2.03 |
| Vapour Pressure | 0.0±1.3 mmHg at 25°C |
| Index of Refraction | 1.657 |
| InChIKey | UOMKBIIXHQIERR-UHFFFAOYSA-N |
| SMILES | O=C(O)Cn1c2ccccc2c(=O)c2ccccc21 |
Toxicological Information
CHEMICAL IDENTIFICATION |
ACUTE TOXICITY DATA - TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - hamster
- DOSE/DURATION :
- 1022 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 6,408,1981
Safety Information
| Symbol | GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H315-H319-H335 |
| Precautionary Statements | P261-P305 + P351 + P338 |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
| Hazard Codes | Xi: Irritant; |
| Risk Phrases | R36/37/38 |
| Safety Phrases | 26 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
| RTECS | AR7190000 |
| HS Code | 2933990090 |
Customs
| HS Code | 2933990090 |
|---|---|
| Summary | 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
Articles30
More Articles| [The interferon production by rat spleen and thymus lymphocytes in condititons of hypoacidity]. Fiziol. Zh. 59(1) , 84-8, (2013) The interferon production by rat spleen and thymus lymphocytes in conditions of gastric juice hypoacidity, evoked by 28 days of omeprazole treatment, was studied. It was shown that the spontaneous and... | |
| [Experimental justification of approaches to pharmacological correction of delayed disorders caused by acute ethylene glycol poisoning]. Eksp. Klin. Farmakol. 75(11) , 31-4, (2012) The development of delayed disorders caused by acute ethylene glycol poisoning has been studied in experiments on male rats. These disorders include chronic renal failure and secondary combined immuno... | |
| Species-specific detection of the antiviral small-molecule compound CMA by STING. EMBO J. 32(10) , 1440-50, (2013) Extensive research on antiviral small molecules starting in the early 1970s has led to the identification of 10-carboxymethyl-9-acridanone (CMA) as a potent type I interferon (IFN) inducer. Up to date... |
Synonyms
| cridanimod |
| (9,10-Dihydro-9-oxo-10-acridinyl)acetic acid |
| MFCD00157050 |
| (9-Oxo-10(9H)-acridinyl)acetic acid |
| 9-Oxo-10(9H)-acridineacetic acid |
| (9-oxoacridin-10(9H)-yl)acetic acid |
| 10-(Carboxymethyl)-9(10H)-acridone |
| 2-(9-oxoacridin-10-yl)acetic acid |
| 10(9H)-Acridineacetic acid, 9-oxo- |
| 9-Oxoacridine-10-acetic Acid |
| 10-(Carboxymethyl)-9(10H)acridone |
| (9,10-Dihydro-9-oxo-10-acridinyl)acetic acid (10-(Carboxymethyl)-9(10H)acridone |
